RE:RE:RE:Another Target Expression Comparison: Trop-2I see. It is important to specify here that they state that sortilin is expressed in 59% of all TNBC subtypes, compare to PD-1 expressed in 19% of cancer subtypes. So it is not an expression of the receptor itself that is three times higher in TNBC. In other words, it is not three times more sortilin receptors on membranes of TNBC cells in general. I just specify that because when I read you first it's what I thought.
One thing that is important in the case of TH1902 in TNBC that is important, is that it is likely that most TNBC patients will be no more responsive to taxanes injected alone. I say that because yesterday, in the article on the phase I/II of Trodelvy on TNBC, 98% of the patients in the study had been previouly treated with taxanes (106 patients out of 108). So TH1902 will need to work as a delivery and concentration tool of docetaxel inside cancer cells, but this higher concentration and the location of docetaxel inside the cell will have to overcome the inefficacy of docetaxel when injected alone. So it won't be a walk in the park. Proof of concept will have to be etablished on patients on which docetaxel injected alone no longer works. We need to remember that. In many cases, TH1902 might work well as an intracellular drug delivery tool, but the limiting factor on efficacy will be docetaxel. That's why establishing the proof of concept is so important because if it done, it will only be the first step. TH19P01 will be like a missile on which they will be able, in the future, to put more lethal warheads.
Wino115 wrote: It is in the fourth section (Discussion) in their paper published in Cancer Science May 2021. It's the second to last paragraph in the whole paper. They mention that Sort1 was "upregulated" in around 60% of TNBC subtypes while PD-1 was upregulated in only 19% of TNBC. THTX's 60% in TNBC is from the paper by Roselli & Pundavela (Oncotarget 2015, Sortilin is assoc with breast cancer aggresiveness...". The PD-1 stat is from Sun, Lee "Expression of PD-L1 in TNBC based on different immunohitochemical antibodies. J Transl Med 2016.
Love it if you can find more definitive stats like that around other tumor types and other targets being used for cancer treatements.
jfm1330 wrote: Where did Thera release that info?
Wino115 wrote: So we learned from THTX that sortilin overexpression is 3x that of PD-1 (Keytruda's target) in tumors.